Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
Abstract Background The characterization and comparison of gene expression (GE) and intrinsic subtypes (IS) changes induced by neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) in hormone receptor-positive(HR+)/HER2-low vs. HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association of HER2 status with pathologic responses and prognosis in HR+/HER2-negative BC is controversial and restricted to NACT-treated disease. Similarly, a temporal heterogeneity in HER2 status has been described only with NACT.Methods We retrospectively recruited a consecutive cohort of 186 patients with stage I-IIIB HR+/HER2-negative BC treated with neoadjuvant therapy (NAT). Available diagnostic biopsies and surgical samples were characterized for main pathological features, PAM50 intrinsic subtypes (IS) and risk-of-relapse (ROR)-P score, and GE. Associations with pathologic complete response (pCR), residual cancer burden (RCB)-0/I, event-free survival (EFS) and overall survival (OS) based on HER2 status were assessed. Pre/post pathologic/molecular changes were analyzed in matched samples.Results The HER2-low (62.9%) and HER2-0 (37.1%) cohorts did not differ significantly in main baseline features, treatments administered, breast conserving surgery (BCS), pCR and RCB-0/I rates, EFS and OS. NAT induced, regardless of HER2 status, a significant reduction of ER/PgR and Ki67, a downregulation of PAM50 proliferation- and luminal-related genes/signatures, an upregulation of selected immune genes and a shift towards less aggressive IS and lower ROR-P. Moreover, 25% of HER2-0 changed to HER2-low and 34% HER2-low became HER2-0. HER2 shifts were significant after NACT (p<0.001), not NET (p=0.063), with consistentERBB2mRNA level dynamics. HER2 changes were not associated to EFS/OS.Conclusions HER2 status changes after NAT in ∼1/4 of cases, mostly after NACT. Targeted adjuvant strategies should be investigated accordingly. Molecular downstaging with current chemo/endocrine agents and immunotherapy should not rely on HER2 immunohistochemical levels in HR+/HER2-negative BC. Instead, HER2-low-targeted approaches should be explored to pursue more effective and/or less toxic dimensional downstaging.Highlights <jats:list list-type="order">Hormone receptor-positive (HR+)/HER2-low and HER2-0 breast cancer (BC) showed similar post-neoadjuvant surgical outcomes.Neoadjuvant therapy (NAT) induced a shift towards less aggressive subtypes and ROR-P classes regardless of HER2 status.All NAT strategies induced a downregulation of proliferation- and luminal biology-related genes, regardless of HER2 status.NAT induced changes in HER2 status, with a discordance rate of 34% and HER2-low showing higher instability than HER2-0.HER2 status at baseline, after surgery and its dynamics were not significantly associated to long-term outcomes..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 02. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schettini, Francesco [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.12.27.23299114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042021138 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042021138 | ||
| 003 | DE-627 | ||
| 005 | 20240103090323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231230s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.27.23299114 |2 doi | |
| 035 | |a (DE-627)XBI042021138 | ||
| 035 | |a (biorXiv)10.1101/2023.12.27.23299114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schettini, Francesco |e verfasserin |0 (orcid)0000-0001-6561-1919 |4 aut | |
| 245 | 1 | 0 | |a Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background The characterization and comparison of gene expression (GE) and intrinsic subtypes (IS) changes induced by neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) in hormone receptor-positive(HR+)/HER2-low vs. HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association of HER2 status with pathologic responses and prognosis in HR+/HER2-negative BC is controversial and restricted to NACT-treated disease. Similarly, a temporal heterogeneity in HER2 status has been described only with NACT.Methods We retrospectively recruited a consecutive cohort of 186 patients with stage I-IIIB HR+/HER2-negative BC treated with neoadjuvant therapy (NAT). Available diagnostic biopsies and surgical samples were characterized for main pathological features, PAM50 intrinsic subtypes (IS) and risk-of-relapse (ROR)-P score, and GE. Associations with pathologic complete response (pCR), residual cancer burden (RCB)-0/I, event-free survival (EFS) and overall survival (OS) based on HER2 status were assessed. Pre/post pathologic/molecular changes were analyzed in matched samples.Results The HER2-low (62.9%) and HER2-0 (37.1%) cohorts did not differ significantly in main baseline features, treatments administered, breast conserving surgery (BCS), pCR and RCB-0/I rates, EFS and OS. NAT induced, regardless of HER2 status, a significant reduction of ER/PgR and Ki67, a downregulation of PAM50 proliferation- and luminal-related genes/signatures, an upregulation of selected immune genes and a shift towards less aggressive IS and lower ROR-P. Moreover, 25% of HER2-0 changed to HER2-low and 34% HER2-low became HER2-0. HER2 shifts were significant after NACT (p<0.001), not NET (p=0.063), with consistentERBB2mRNA level dynamics. HER2 changes were not associated to EFS/OS.Conclusions HER2 status changes after NAT in ∼1/4 of cases, mostly after NACT. Targeted adjuvant strategies should be investigated accordingly. Molecular downstaging with current chemo/endocrine agents and immunotherapy should not rely on HER2 immunohistochemical levels in HR+/HER2-negative BC. Instead, HER2-low-targeted approaches should be explored to pursue more effective and/or less toxic dimensional downstaging.Highlights <jats:list list-type="order">Hormone receptor-positive (HR+)/HER2-low and HER2-0 breast cancer (BC) showed similar post-neoadjuvant surgical outcomes.Neoadjuvant therapy (NAT) induced a shift towards less aggressive subtypes and ROR-P classes regardless of HER2 status.All NAT strategies induced a downregulation of proliferation- and luminal biology-related genes, regardless of HER2 status.NAT induced changes in HER2 status, with a discordance rate of 34% and HER2-low showing higher instability than HER2-0.HER2 status at baseline, after surgery and its dynamics were not significantly associated to long-term outcomes. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Nucera, Sabrina |4 aut | |
| 700 | 1 | |a Brasó-Maristany, Fara |4 aut | |
| 700 | 1 | |a De Santo, Irene |4 aut | |
| 700 | 1 | |a Pascual, Tomás |4 aut | |
| 700 | 1 | |a Bergamino, Milana |4 aut | |
| 700 | 1 | |a Galván, Patricia |4 aut | |
| 700 | 1 | |a Conte, Benedetta |4 aut | |
| 700 | 1 | |a Seguí, Elia |4 aut | |
| 700 | 1 | |a García Fructuoso, Isabel |4 aut | |
| 700 | 1 | |a Gómez Bravo, Raquel |4 aut | |
| 700 | 1 | |a Rivera, Pablo |4 aut | |
| 700 | 1 | |a Belén Rodríguez, Ana |4 aut | |
| 700 | 1 | |a Martínez-Sáez, Olga |4 aut | |
| 700 | 1 | |a Ganau, Sergi |4 aut | |
| 700 | 1 | |a Sanfeliu, Esther |4 aut | |
| 700 | 1 | |a González-Farre, Blanca |4 aut | |
| 700 | 1 | |a Vidal, Maria |4 aut | |
| 700 | 1 | |a Adamo, Barbara |4 aut | |
| 700 | 1 | |a Cebrecos, Isaac |4 aut | |
| 700 | 1 | |a Mension, Eduard |4 aut | |
| 700 | 1 | |a Oses, Gabriela |4 aut | |
| 700 | 1 | |a Jares, Pedro |4 aut | |
| 700 | 1 | |a Vidal-Sicart, Sergi |4 aut | |
| 700 | 1 | |a Mollà, Meritxell |4 aut | |
| 700 | 1 | |a Muñoz, Montserrat |4 aut | |
| 700 | 1 | |a Prat, Aleix |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 02. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.27.23299114 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 01 | ||